Mathew Aby J.
EVP & Chief Scientific Officer
Mathew Aby J. has filed 15 SEC Form 4 filings (20 transaction rows) across 1 company, with disclosures dating back to 2025. 13 of those filings fall inside the rolling window. Most recent filing: Oct 9, 2026.
On the most recent filing, Mathew Aby J. is listed as EVP & Chief Scientific Officer at BIOLIFE SOLUTIONS INC. Inside the rolling window, Mathew Aby J. reported no open-market purchases and 4 open-market sales totaling $51K in BLFS. The largest disclosed transaction in the window is a sale of 631 BLFS shares on Dec 9, 2025, worth $16K.
Companies traded
Other insiders at BLFS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$51K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Mathew Aby J. made?
Mathew Aby J. has filed 15 SEC Form 4 filings (20 transaction rows) across 1 company since 2025.
Which companies does Mathew Aby J. trade?
Mathew Aby J. has filed SEC Form 4 disclosures for 1 company, including BLFS.
When was Mathew Aby J.'s most recent SEC Form 4 filing?
Mathew Aby J.'s most recent SEC Form 4 filing on Tracefour is dated Oct 9, 2026.
What is Mathew Aby J.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Mathew Aby J. is listed as EVP & Chief Scientific Officer.
What is Mathew Aby J.'s total buy and sell value in the current window?
Inside the rolling retention window, Mathew Aby J. bought $0 and sold $51K based on SEC Form 4 filings.
What was Mathew Aby J.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 631 BLFS shares on 2025-12-09, worth $16K, per SEC Form 4 filings.